Dermatological Findings in Fibromyalgia Syndrome and Their Effects on Quality of Life, Clinical Findings, and Depression
Gulseren Dost Surucu 1 * , Esra Inan Dogan 2
More Detail
1 Adiyaman University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Adiyaman, Turkey2 Adiyaman University, Faculty of Medicine, Department of Dermatology, Adiyaman, Turkey* Corresponding Author

Abstract

Purpose: The aim was to investigate the skin findings in patients with Fibromyalgia Syndrome (FMS), and the relations of these findings with the clinical symptoms of the disease, quality of life and depression levels of the patient.
Materials and Methods: A total of 77 patients with FMS were included in the study as the study group, 74 individuals were included as the control group. The pain levels were evaluated with Visual Analogue Scale (VAS). The short form-36 (SF-36) was used to evaluate the quality of life levels of the patients. The Beck Depression Scale (BDS) was used to evaluate the depression levels of the patients. All participants were evaluated by the same dermatology specialist.
Results: Although 37.1% patients who had FMS had at least one cutaneous symptom, 19.9% of the control group had at least one cutaneous symptom (p<0.01). According to the BDS, significant increases were detected in FMS patients (p=0.001). Significant decreases were detected in terms of all SF-36 parameters in the FMS group (p=0.001). There was at least one dermatological disease in 43% of the patients, and in 20.5% of the controls. Although no significant differences were detected between BDS and VAS scores of the FMS patients with and without dermatological findings, SF-36 total score and physical role strength score were found to be significantly lower in the patients who had dermatological symptoms.
Conclusions: It must be known that there may be dermatological symptoms in FMS, a more multidisciplinary approach must be used in treatment and follow-up.

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Research Article

J CLIN EXP INVEST, Volume 13, Issue 1, March 2022, Article No: em00791

https://doi.org/10.29333/jcei/11665

Publication date: 02 Feb 2022

Article Views: 1198

Article Downloads: 920

Open Access References How to cite this article